Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 28, 2017

View Archived Issues

GSK to incorporate Owlstone's Breath Biopsy platform into danirixin clinical program

Bicycle Therapeutics creates novel peptide-toxin conjugates specific for MT1-MMP

aTyr Pharma initiates dosing in first-in-human trial of iMod.Fc

Novel HIV integrase inhibitors discovered at ViiV Healthcare

Sunshine Lake Pharma patents novel memantine prodrugs

Catalyst Pharmaceuticals reports topline results from phase III study of Firdapse

Kyowa Hakko Kirin licenses tenapanor rights in Japan from Ardelyx

FDA grants priority review to Dova's NDA for avatrombopag

Otonomy discontinues commercial support for Otiprio, focuses resources on otology pipeline

EMA accepts Macrilen MAA for adult growth hormone deficiency

Biogen and Alkermes collaborate to develop and commercialize ALKS-8700 for MS

VE-2851, a promising novel thrombin inhibitor with low bleeding risk

FDA grants fast track designation to Stealth Biotherapeutics' elamipretide

Medeor Therapeutics closes series B financing

Prima BioMed changes name to Immutep

EMA accepts Tagrisso submission in first-line EGFR-mutated NSCLC

KY-1044 elicits long-term in vivo antitumor efficacy

AbbVie announces launch of Maviret in Japan

Eureka Therapeutics cleared by FDA for phase I study of ET-190L1-Artemis T cells

In vitro and in vivo characterization of the novel anti-CTLA-4 antibody ADU-1604

Long-lasting neutralizing antibody responses seen with dengue vaccine KD-382 in cynomolgus monkeys

Novel gene variations linked to common forms of epilepsy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...